北京因诺惟康医药科技有限公司（InnoVec Biotherapeutics Inc. or InnoVecBio）是一家致力于基因编辑递送技术和药物开发的公司。本着“In China For Global”的理念，公司专注于开发精准安全高效的组织靶向性载体，致力于解决人体所有组织和器官的基因递送问题，从而使基因治疗能被广泛地应用各种疾病和人群当中。 递送技术方面，在针对受体开发载体的基础上，因诺惟康开发了多款可以用作眼睛玻璃体注射的AAV载体，在小动物和大动物上经过反复验证，基于这些载体，因诺惟康正在推进临床研究。同时靶向肝脏，心脏，神经，肌肉等组织的载体也在开发过程中。为了克服病毒载体免疫原性引起的毒性和不能重复注射的问题，因诺惟康也正在开发全人源的类病毒递送载体，用人源的蛋白组成核酸递送载体，理论上可以大幅度减少甚至消除递送载体的免疫原性问题。 在自身研发的玻璃体注射载体的基础上，因诺惟康正在紧锣密鼓的推进产品开发，包括视网膜劈裂（XLRS），全色盲（CNGA3），色素变性（RDH12），青少年黄斑病性（ABCA4）等基因突变引起的遗传性视网膜疾病以及视网膜推行病变，老年性黄斑变性等常见视网膜疾病。同时因诺惟康也在积极探索眼科领域以外疾病的基因疗法，包括阿尔兹海默症，神经包涵体病，肌肉减少症等。

Splice Bio is a biotechnology company exploiting protein splicing intended to develop next-generation gene therapies. The company uses proprietary conjugation that helps in the development and production of a preferred class of biotherapeutics, including antibody-drug conjugates, overcoming limitations of the currently used methods, enabling clients to easily develop biological drugs.In February 2022, SpliceBio completed an oversubscribed €50 million series A financing co-led by UCB Ventures and Ysios Capital

Mezzion Pharma, previously known as Dong-A Pharmtech (a former subsidiary of Dong-A Socio Holdings), is a biotech company focused on the development of drugs for multiple diseases, including erectile dysfunction, prostatic hyperplasia, hypertension and pulmonary arterial hypertension.The company is headquartered in Korea.In January 2017, Mezzion had filed a suit for damages against Dr Reddy's in New Jersey State court alleging that Dr Reddy's committed fraud relating to Dr Reddy's hiding significant deficiencies in its FDA cGMP practices, and misrepresenting its compliance to Mezzion. The suit notes that Dr Reddy's repeatedly represented to Mezzion that it was compliant with FDA regulations, and that it hid its misconduct from Mezzion. The suit also states that Dr Reddy's misconduct was the sole reason given by the FDA to deny approval of Mezzion's NDA for udenafil for the treatment of erectile dysfunction and for FDA's refusal to grant marketing approval of Mezzion's udenafil finished drug product. As a